Agency leadership heard a briefing on cannabis-related legislation still active and otherwise, including both agency requests and bills introduced by other stakeholders.
The committee heard the cannabis commodity commission bill and passed WSLCB’s request legislation to expand agency rulemaking power and DOH authority over marijuana products.
The Board superseded its emergency rules on vitamin E acetate in vapor products then heard concerns about ingredient disclosure forms and truth in agency messaging.
The Legislature planned to convene 8 public hearings and at least 8 executive sessions across 7 committee meetings while the WSLCB prepared to adopt a slate of new emergency rules.
WSLCB leadership was briefed on and discussed cannabis-related legislation active at the legislature, including the agency’s three recently introduced request bills.
New details on the WSLCB’s legislative agenda, a Regulators Roundtable redux, plus an update on testing labs, the traceability contract, and the Hillard Heintze report.
The Board discussed the medical cannabis patient registry, reviewed allegations of unjust treatment from members of Black Excellence in Cannabis, and heard a rulemaking update.
Agency leadership learned about the Healthy Youth Survey (HYS) which provides perspective on alcohol, cannabis, and vapor product use by Washington children in grades 6-12.
Agency leadership heard a substantial legislative update in the run up to the 2020 session and hints about the agency’s shifting vision of cannabis supply chain traceability.
Board members reported the Tribal Advisory Council was poised for demotion, the Cannabis 2.0 project had lost momentum, and vapor product regulation continued to cloud the horizon.